Dr. Michael Green interviews Dennis Edmonds, CEO of Kazera Global

July 20, 2022 | Posted by

Dr. Michael Green, resources analyst at Align Research, interviews Dennis Edmonds, CEO of Kazera Global.

Click the play button below to listen to the audio.

Key questions posed:

1. Could you outline the truly transformational deal on the lithium potential of the tantalum project?

2. Does this deal mean that Kazera has lost control over the lithium?

3. What does this deal mean for the tantalum?

4. What are the implications of this deal for the parent company and the operation in South Africa?

5. Looks to me as though we might have two transformational deals here. The installation of the Pan Plant on the alluvial diamond project in South Africa looks like a masterstroke which hasn’t cost Kazera a penny. Please tell me more.

6. What does the news flow look like for the rest of the year?

To read our recent coverage on Kazera CLICK HERE

Kazera Global is a research client of Align Research. Align Research is the largest shareholder in Kazera Global and cannot be seen to be impartial in relation to the share price outcome. All employees and analysts are bound to the company’s dealing policy ensuring open and adequate disclosure. Full details can be found on our website here (“Legals”).

This is a marketing communication and cannot be considered independent research. Nothing in this report should be construed as advice, an offer, or the solicitation of an offer to buy or sell securities by us. As we have no knowledge of your individual situation and circumstances the investment(s) covered may not be suitable for you. You should not make any investment decision without consulting a fully qualified financial advisor.

Your capital is at risk by investing in securities and the income from them may fluctuate. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results. The marketability of some of the companies we cover is limited and you may have difficulty buying or selling in volume. Additionally, given the smaller capitalisation bias of our coverage, the companies we cover should be considered as high risk. You should also assume, given that the majority of Align’s fees are received in stock, that for general corporate cash management purposes including taxation, that divestments of investments held will take place as and when, in Align’s sole discretion, it is deemed appropriate.

This financial promotion has been approved by Align Research Limited